≥ 99% purity
Each batch is assayed by HPLC and verified to a purity of 99% or greater before release.
Synthetic GHRH analog · Laboratory research reference
A high‑purity synthetic analog of growth‑hormone‑releasing hormone (GHRH) — the short‑acting, non‑DAC form (Modified GRF 1‑29) with an in‑vitro half‑life of approximately 30 minutes. Supplied as a 10 mg lyophilized reference compound for laboratory research.
Reference data · molecular profile · specifications · research citations — for CJC‑1295 (No DAC) 10 mg.
⚠ Sold strictly as a research chemical — not for human consumption. Not suitable for persons under 21. Price shown for reference; availability & checkout on the main store.
GHRH analog
t½ ≈ 30 min
01 — Overview
A peptide is a short chain of amino acids — a small, protein-like molecule. CJC‑1295 belongs to a family studied for how it interacts with the body's growth-hormone signalling system. This page is a factual reference written for researchers — it is not health advice, and the product is not for human use.
CJC‑1295 is a synthetic peptide analog of growth‑hormone‑releasing hormone (GHRH). This is the No‑DAC variant — often referred to as Modified GRF (1‑29) — the unconjugated form that does not carry a Drug Affinity Complex. As a result it is short‑acting, with an in‑vitro half‑life characterized at roughly 30 minutes, and is handled frequently in research rather than on a weekly basis.
It is classified in the literature as a growth‑hormone secretagogue and is studied as a reference standard in peptide research. The compound is supplied as a sterile lyophilized powder (10 mg / vial), reconstituted with bacteriostatic water for laboratory handling. This page describes the material's characterization only and makes no claim of any effect in humans or animals.
02 — Molecular profile
Structural characteristics of the reference compound. Descriptive only — not a description of effects.
A modified GRF (1‑29) fragment of the growth‑hormone‑releasing hormone sequence, synthesized to a defined, stabilized structure.
Unlike the long‑acting DAC version, this variant carries no albumin‑binding complex — it is the unconjugated peptide.
Without albumin binding, the in‑vitro half‑life is characterized at approximately 30 minutes.
No DAC The defining feature of this variant is the absence of the Drug Affinity Complex: it is the short‑acting, unconjugated form of CJC‑1295 (Modified GRF 1‑29), distinct from the long‑acting DAC version.
| Property | No‑DAC (this page) | With DAC |
|---|---|---|
| Also known as | Modified GRF (1‑29) | CJC‑1295 DAC |
| Albumin binding | No | Yes (Drug Affinity Complex) |
| Est. half-life | ≈ 30 minutes (short-acting) | ≈ 8–10 days (long-acting) |
| Research handling | Frequent | Weekly |
03 — Quality
Factual product attributes of the reference material — verified by analysis, not claims of biological effect.
Each batch is assayed by HPLC and verified to a purity of 99% or greater before release.
Produced in an ISO 9001:2015 / GMP-aligned facility under documented quality controls.
Independent analysis available; Certificate of Analysis (CoA) provided per batch on request.
Lyophilized 10 mg vials with optional custom labeling for laboratory inventory and research workflows.
04 — Specifications
| Compound | CJC‑1295 without DAC (Modified GRF 1‑29) |
|---|---|
| Classification | GHRH analog · Growth-hormone secretagogue |
| Form | Lyophilized powder |
| Content | 10 mg per vial |
| Purity | ≥ 99% (HPLC verified) |
| Reconstitution | Bacteriostatic water |
| Est. half-life | ≈ 30 minutes (short-acting) |
| Storage | Lyophilized: cool & dry, protected from light. Reconstituted: refrigerated. |
| Intended use | Laboratory & research purposes only |
05 — FAQ
This page profiles the No‑DAC variant (Modified GRF 1‑29), the short‑acting form with an in‑vitro half‑life of about 30 minutes. The DAC (Drug Affinity Complex) version binds to albumin in the bloodstream and is much longer‑acting (~8–10 days).
Yes. Every batch is assayed by HPLC to ≥99% purity and is tested in third‑party laboratories. A Certificate of Analysis (CoA) is available per batch on request.
No. It is sold exclusively as a research chemical and is not intended for human consumption. It is supplied for laboratory and research purposes only.
As a sterile lyophilized (freeze‑dried) powder, 10 mg per vial. In research settings it is reconstituted with bacteriostatic water before handling.
The lyophilized powder is kept cool, dry and away from light. Once reconstituted, it is stored refrigerated.
This page is an information profile. To check live availability, bulk pricing and complete a purchase, visit the main Testosterone Muscle store.
06 — Key terms
Plain-language definitions of the technical terms used on this page.
07 — References
Peer-reviewed literature on CJC-1295 and GHRH analogs, provided for educational reference only. Linking does not imply any human-use recommendation.
Live stock and batch Certificates of Analysis are handled on the main Testosterone Muscle store.
This product is supplied strictly for laboratory research use only. It is NOT for human or veterinary use, and not for diagnostic, therapeutic, prophylactic, cosmetic, or food/supplement use. It is not a drug, and no statement on this page should be interpreted as a description of any effect in humans or animals.
These statements have not been evaluated by the Food and Drug Administration (FDA) or any equivalent regulatory authority. This product is not intended to diagnose, treat, cure, or prevent any disease. All information is provided for chemical and educational reference only and does not constitute medical advice.
By purchasing, the buyer confirms they are a qualified researcher or institution acquiring the material for legitimate laboratory purposes, and accepts sole responsibility for its lawful handling, storage, and disposal in accordance with all applicable local regulations. Not suitable for persons under 21 years of age.